Literature DB >> 27644548

Management and therapeutic perspectives in amyotrophic lateral sclerosis.

Stéphane Mathis1, Philippe Couratier2, Adrien Julian3, Jean-Michel Vallat4, Philippe Corcia5, Gwendal Le Masson1.   

Abstract

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disorder affecting both upper and lower motor neurons. Despite much research and effort, no clear insights into a unifying hypothesis for the pathogenesis has so far emerged for this disease. Areas covered: We review the main pathophysiological hypotheses and the potential therapeutic targets in ALS, as well as the management of these patients (in order to improve their survival and quality of life). Expert commentary: ALS is a complex neurodegenerative disease, these days considered as a multisystem disorder with predominant motor symptoms (and various clinical forms). Further comprehension of the pathophysiology of this disease is required, although pathophysiological mechanisms (such as TDP-43) show promise in the search for new therapies. There is still no curative treatment for ALS, but the emergence of multidisciplinary specialized ALS clinics has increased both the quality of life and the survival of these patients.

Entities:  

Keywords:  ALS; Amyotrophic lateral sclerosis; animal models; management; riluzole; treatment

Mesh:

Year:  2016        PMID: 27644548     DOI: 10.1080/14737175.2016.1227705

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  11 in total

Review 1.  RNA-binding proteins with prion-like domains in health and disease.

Authors:  Alice Ford Harrison; James Shorter
Journal:  Biochem J       Date:  2017-04-07       Impact factor: 3.857

Review 2.  Incorporating upper motor neuron health in ALS drug discovery.

Authors:  Ina Dervishi; P Hande Ozdinler
Journal:  Drug Discov Today       Date:  2018-01-10       Impact factor: 7.851

Review 3.  Body mass index and survival from amyotrophic lateral sclerosis: A meta-analysis.

Authors:  Efthimios Dardiotis; Vasileios Siokas; Maria Sokratous; Zisis Tsouris; Athina-Maria Aloizou; Desponia Florou; Metaxia Dastamani; Alexios-Fotios A Mentis; Alexandros G Brotis
Journal:  Neurol Clin Pract       Date:  2018-10

4.  Staging model for amyotrophic lateral sclerosis in Singapore.

Authors:  Yuan Teck Tay; Josiah Y H Chai; Kamilah Bte Shekh Jabin; Kexin Ang
Journal:  Singapore Med J       Date:  2022-07       Impact factor: 3.331

Review 5.  Implications of white matter damage in amyotrophic lateral sclerosis (Review).

Authors:  Ting Zhou; Tina Khorshid Ahmad; Kiana Gozda; Jessica Truong; Jiming Kong; Michael Namaka
Journal:  Mol Med Rep       Date:  2017-08-07       Impact factor: 2.952

6.  Minimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners.

Authors:  Martin Matharan; Stéphane Mathis; Sarah Bonabaud; Louis Carla; Antoine Soulages; Gwendal Le Masson
Journal:  Neurol Res Int       Date:  2020-05-11

Review 7.  Novel therapeutic targets for amyotrophic lateral sclerosis.

Authors:  Gitika Batra; Manav Jain; Rahul Soloman Singh; Amit Raj Sharma; Ashutosh Singh; Ajay Prakash; Bikash Medhi
Journal:  Indian J Pharmacol       Date:  2020-01-16       Impact factor: 1.200

Review 8.  Defective Oligodendroglial Lineage and Demyelination in Amyotrophic Lateral Sclerosis.

Authors:  Elisabeth Traiffort; Séverine Morisset-Lopez; Mireille Moussaed; Amina Zahaf
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

Review 9.  Pathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis.

Authors:  Ali Yousefian-Jazi; YunHee Seol; Jieun Kim; Hannah L Ryu; Junghee Lee; Hoon Ryu
Journal:  Cells       Date:  2020-12-15       Impact factor: 6.600

Review 10.  RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis.

Authors:  Stéphane Mathis; Gwendal Le Masson
Journal:  Biomedicines       Date:  2018-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.